Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hans Chung

Showing results (41-50 of 55) with videos related to

Pageof 6
Sort By:
International Journal of Radiation Oncology, Biology, Physics|November 5, 2015
Tumor Response After Stereotactic Body Radiation Therapy to Nonspine Bone Metastases: An Evaluation of Response CriteriaRachel McDonald, Linda Probyn, Ian Poon, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2016
Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate CancerHima Bindu Musunuru, Melanie Davidson, Patrick Cheung, et al.
Current Opinion in Supportive and Palliative Care|January 29, 2026
Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature reviewDavid Chen, Jane Jomy, Tony Ning, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation StudyYasir Alayed, Andrew Loblaw, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|November 17, 2018
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal IrradiationYasir Alayed, Patrick Cheung, Danny Vesprini, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
Annals of Palliative Medicine|April 29, 2016
Radiological changes on CT after stereotactic body radiation therapy to non-spine bone metastases: a descriptive seriesNicholas Chiu, Linda Probyn, Srinivas Raman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Pageof 6

Showing results (41-50 of 55) with videos related to

Sort By:
Pageof 6
International Journal of Radiation Oncology, Biology, Physics|November 5, 2015
Tumor Response After Stereotactic Body Radiation Therapy to Nonspine Bone Metastases: An Evaluation of Response CriteriaRachel McDonald, Linda Probyn, Ian Poon, et al.
International Journal of Radiation Oncology, Biology, Physics|March 31, 2016
Predictive Parameters of Symptomatic Hematochezia Following 5-Fraction Gantry-Based SABR in Prostate CancerHima Bindu Musunuru, Melanie Davidson, Patrick Cheung, et al.
Current Opinion in Supportive and Palliative Care|January 29, 2026
Comparison of the EORTC QLQ PR25 and the FACT-P for assessing quality of life in patients with prostate cancer - an updated literature reviewDavid Chen, Jane Jomy, Tony Ning, et al.
International Journal of Radiation Oncology, Biology, Physics|April 20, 2019
Stereotactic Body Radiation Therapy Boost for Intermediate-Risk Prostate Cancer: A Phase 1 Dose-Escalation StudyYasir Alayed, Andrew Loblaw, William Chu, et al.
International Journal of Radiation Oncology, Biology, Physics|November 17, 2018
SABR in High-Risk Prostate Cancer: Outcomes From 2 Prospective Clinical Trials With and Without Elective Nodal IrradiationYasir Alayed, Patrick Cheung, Danny Vesprini, et al.
International Journal of Radiation Oncology, Biology, Physics|September 18, 2024
Stereotactic Radiation Therapy for Localized Prostate Cancer: 10-Year Outcomes From Three Prospective TrialsThomas A C Kennedy, Wee Loon Ong, Harvey Quon, et al.
Annals of Palliative Medicine|April 29, 2016
Radiological changes on CT after stereotactic body radiation therapy to non-spine bone metastases: a descriptive seriesNicholas Chiu, Linda Probyn, Srinivas Raman, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|May 17, 2020
Accelerating prostate stereotactic ablative body radiotherapy: Efficacy and toxicity of a randomized phase II study of 11 versus 29 days overall treatment time (PATRIOT)Yasir Alayed, Harvey Quon, Aldrich Ong, et al.
International Journal of Radiation Oncology, Biology, Physics|July 7, 2023
To Boost or Not to Boost: Pooled Analyses From 2-Fraction SABR Trials for Localized Prostate CancerWee Loon Ong, Patrick Cheung, Hans Chung, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 24, 2023
Dosimetric correlates of toxicities and quality of life following two-fraction stereotactic ablative radiotherapy (SABR) for prostate cancerWee Loon Ong, Melanie Davidson, Patrick Cheung, et al.
Pageof 6